Business Context and Reporting Period
This Form 8-K was filed by Ainos, Inc. on July 12, 2024, reporting events occurring on July 8, 2024. The Company is incorporated in Texas and trades on The Nasdaq Stock Market LLC under the symbols AIMD (Common Stock) and AIMDW (Warrants). The filing primarily addresses an amendment to a material definitive agreement with Taiwan Carbon Nano Technology Corporation ("TCNT"), a majority shareholder of a Cayman Islands entity that holds approximately 39% of Ainos's voting power.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figures disclosed relate to the terms of the agreement with TCNT:
- Development Fee: A total fee of NT$5 million (approximately USD$161,000) was paid for five years of development commencing in 2024.
- Patent Use Fee: A monthly fee of US$95,000 (plus 5% sales tax) applies for the non-exclusive use of patents related to volatile organic compounds ("VOC") and point-of-care testing ("POCT").
Material Changes
The material change reported is the execution of a "Second Addendum Agreement" on July 8, 2024, modifying the original Product Development Agreement dated August 1, 2021, and a First Addendum dated January 9, 2024. Key changes include:
- Extension of Patent Rights: The non-exclusive use of specific VOC and POCT patents is extended for an additional three months, covering the period from July 2024 to September 2024.
- Payment Obligation: The Company is obligated to pay the Patent Use Fee for this additional three-month period.
- Scope of Support: TCNT continues to provide facilities, equipment, mass production process technology, and ISO9001/ISO13485 management support, excluding procurement of parts, raw materials, rental fees, and utilities.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future performance, or a discussion of general risks beyond the contractual obligations. The agreement is contingent on the continued co-development of pharmaceutical and medical device products. The filing notes that the description of the Second Addendum is qualified by reference to the full text of the agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the total cash outflow impact of the extended Patent Use Fee (US$95,000/month + 5% tax) for the July-September 2024 period.
- Review the full text of the Second Addendum Agreement (Exhibit 10.1) for specific termination clauses or performance milestones.
- Confirm the current cash position of Ainos, Inc. to assess liquidity relative to the new payment obligations, as this filing does not provide current balance sheet data.
- Monitor the relationship with TCNT, given its significant indirect ownership stake (approx. 39% voting power) and role as a development partner.